Who are Linaprazan glurate - Low dose's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tegoprazan 50 mg, tablets, orally, qd, Tegoprazan 50 mg, Vonoprazan Tablets, Fexuprazan Hydrochloride, Linaprazan glurate - High dose, Vonoprazan, Amoxicillin, Levofloxacin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/linaprazan-glurate-low-dose.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Linaprazan glurate - Low dose — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Linaprazan glurate - Low dose (Linaprazan glurate - Low dose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Potassium-competitive acid blocker (P-CAB). Area: Gastroenterology.

phase 3 Potassium-competitive acid blocker (P-CAB) H+/K+-ATPase (gastric proton pump) Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Linaprazan glurate - Low dose (Linaprazan glurate - Low dose) — Cinclus Pharma Holding AB. Linaprazan is a potassium-competitive acid blocker (P-CAB) that reversibly inhibits the gastric H+/K+-ATPase pump to reduce gastric acid secretion.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Linaprazan glurate - Low dose TARGET	Linaprazan glurate - Low dose	Cinclus Pharma Holding AB	phase 3	Potassium-competitive acid blocker (P-CAB)	H+/K+-ATPase (gastric proton pump)
Tegoprazan 50 mg, tablets, orally, qd	Tegoprazan 50 mg, tablets, orally, qd	Zhang Xiaofeng,MD	marketed	Potassium-competitive acid blocker (P-CAB)	H+/K+-ATPase
Tegoprazan 50 mg	Tegoprazan 50 mg	First People's Hospital of Hangzhou	marketed	Potassium-Competitive Acid Blocker (P-CAB)	H+/K+-ATPase
Vonoprazan Tablets	Vonoprazan Tablets	Humanis Saglık Anonim Sirketi	marketed	Potassium-competitive acid blocker (P-CAB)	H+/K+-ATPase (proton pump)
Fexuprazan Hydrochloride	Fexuprazan Hydrochloride	Daewoong Pharmaceutical Co. LTD.	marketed	Potassium-competitive acid blocker (P-CAB)	H+/K+-ATPase (proton pump)
Linaprazan glurate - High dose	Linaprazan glurate - High dose	Cinclus Pharma Holding AB	phase 3	Potassium-competitive acid blocker (P-CAB)	H+/K+-ATPase (gastric proton pump)
Vonoprazan, Amoxicillin, Levofloxacin	Vonoprazan, Amoxicillin, Levofloxacin	Aga Khan University	phase 3	Potassium-competitive acid blocker (P-CAB)	H+/K+ ATPase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Potassium-competitive acid blocker (P-CAB) class)

Cinclus Pharma Holding AB · 2 drugs in this class
Aga Khan University · 1 drug in this class
Ain Shams University · 1 drug in this class
Daewoong Pharmaceutical Co. LTD. · 1 drug in this class
Humanis Saglık Anonim Sirketi · 1 drug in this class
Zhang Xiaofeng,MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Linaprazan glurate - Low dose — Competitive Intelligence Brief. https://druglandscape.com/ci/linaprazan-glurate-low-dose. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab